INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 December 2016
Net Assets |
£225m |
Net Assets per share |
599p |
Share price |
550p |
Total value of unquoted investments |
£26m |
Total number of portfolio companies |
77 |
Top Ten Holdings
Company Name |
% NAV |
Celgene |
7.6 |
Biogen |
6.7 |
Genmab |
6.3 |
Alexion |
5.9 |
Shire |
5.8 |
Tesaro |
4.6 |
Gilead |
4.5 |
Regeneron |
4.3 |
Amgen |
4.2 |
Novo |
3.4 |
|
----------- |
Total |
53.3 |
Geographical Allocation |
% NAV |
US & Canada |
78 |
Europe & UK |
22 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
89 |
Unquoted |
11 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
58 |
Mid Cap =USD1-10BN |
21 |
Small Cap <USD1BN |
21 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
38 |
Orphan |
12 |
CNS |
11 |
Inflammation |
8 |
Ophthalmology |
5 |
Medtech |
3 |
Other |
23 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
16 JANUARY 2017